Document:

SECURITIES
PURCHASE AGREEMENT

SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of May 20, 2013, by and between Nyxio Technologies Corp. a
Nevada corporation, with executive offices located at 2156 NE Broadway, Portland, Oregon 97232 (the “Company”)
and Continental Equities LLC, a New York limited liability company, with its address at 331 West 57th Street, Suite
206, New York, NY 10019 (the “Investor”).

WHEREAS:

A.               
The Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the Securities Act of 1933, as amended (the “1933 Act”); and

B.                
Investor desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement
an 10% convertible note of the Company, in the form attached hereto as Exhibit “A”, in the principal amount
of Thirteen Thousand Dollars ($13,000.00) (together with any note(s) issued in replacement thereof or as a dividend thereon or
otherwise with respect thereto in accordance with the terms thereof, (the “Note”), convertible into shares
of common stock, par value $0.001 per share, of the Company (the “Common Stock”), upon the terms and subject
to the limitations and conditions set forth in such Note, (the Note, the “Closing Securities” or
the “Securities”).

Capitalized
terms used and not otherwise defined herein shall have the meanings given such terms in the Note.

    	 

    	 

    

NOW
THEREFORE, the Company and the Investor hereby agree as follows:

1.                 
PURCHASE AND SALE OF NOTE.

a.                 
Purchase of Closing Securities. On the Closing Date (as defined below), the Company shall issue and sell to the Investor
and the Investor agrees to purchase from the Company, the Closing Securities in exchange for a cash payment by Investor of Thirteen
Thousand Dollars ($13,000.00).

b.                 
Form of Payment. On the Closing Date (as defined below), (i) the Investor shall pay the purchase price for the
Closing Securities to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by
wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions,
against delivery of the Closing Securities in the principal amount equal to the Purchase Price, and (ii) the Company shall
deliver this Agreement, the Closing Securities and the Registration Rights Agreement duly executed on behalf of the Company, to
the Investor, against delivery of such Purchase Price.

c.                  
Closing Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 6 and
Section 7 below, the date and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”)
shall be 12:00 noon, Eastern Standard Time on May 20, 2013, or such other mutually agreed upon time. The closing of the transactions
contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed
to by the parties.

2.                 
INVESTOR’S REPRESENTATIONS AND WARRANTIES. The Investor represents and warrants to the Company that:

a.                 
Investment Purpose. As of the date hereof, the Investor is purchasing the Closing Securities and the shares of Common
Stock issuable upon conversion or otherwise pursuant to the Note (including, without limitation, such additional shares of Common
Stock, if any, as are issuable (i) on account of interest on the Note, (ii) as a result of the events described in Sections
1.3 and 1.4(g) of the Notes or (iii) in payment of the Standard Liquidated Damages Amount (as defined in Section 2(f) below)
pursuant to this Agreement, such shares of Common Stock being collectively referred to herein as the “Conversion Shares”
for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered
or exempted from registration under the 1933 Act; provided, however, that by making the representations herein,
the Investor does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to dispose
of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act.

b.                 
Accredited Investor Status. The Investor is an “accredited investor” as that term is defined in Rule 501(a)
of Regulation D (an “Accredited Investor”).

c.                  
Reliance on Exemptions. The Investor understands that the Securities are being offered and sold to it in reliance upon
specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
is relying upon the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions
and the eligibility of the Investor to acquire the Securities.

d.                 
Information. The Investor and its advisors, if any, have been, and for so long as the Closing Securities remain outstanding
will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Closing Securities which have been requested by the Investor or its advisors. The Investor
and its advisors, if any, have been, and for so long as the Closing Securities remain outstanding will continue to be, afforded
the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Investor
any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior
to or promptly following such disclosure to the Investor. Neither such inquiries nor any other due diligence investigation conducted
by Investor or any of its advisors or representatives shall modify, amend or affect Investor’s right to rely on the Company’s
representations and warranties contained in Section 3 below. The Investor understands that its investment in the Securities involves
a significant degree of risk. The Investor is not aware of any facts that may constitute a breach of any of the Company’s
representations and warranties made herein.

    	2

    	 

    

e.                  
Governmental Review. The Investor understands that no United States federal or state agency or any other government
or governmental agency has passed upon or made any recommendation or endorsement of the Securities.

f.                  
Transfer or Re-sale. The Investor understands that (i) the sale or re-sale of the Securities has not been and
is not being registered under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred
unless (a) the Securities are sold pursuant to an effective registration statement under the 1933 Act, (b) the Company
shall receive an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable
transactions to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from
such registration, which opinion shall be accepted by the Company, (c) the Securities are sold or transferred to an “affiliate”
(as defined in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”)) of the Investor
who agrees to sell or otherwise transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor,
(d) the Securities are sold pursuant to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the
1933 Act (or a successor rule) (“Regulation S”), and the Company shall have received an opinion of counsel
that shall be in form, substance and scope customary for opinions of counsel in corporate transactions, which opinion shall be
accepted by the Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made only in accordance with the
terms of said Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances in which the
seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act)
may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii)
neither the Company nor any other person is under any obligation to register such Securities under the 1933 Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing or anything else contained
herein to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account
or other lending arrangement.

g.                 
Legends. The Investor understands that the Securities, until such time as the Conversion Shares have been registered
under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities
as of a particular date that can then be immediately sold, the Conversion Shares may bear a restrictive legend in substantially
the following form (and a stop-transfer order may be placed against transfer of the certificates for such Securities):

“The
securities represented by this certificate have not been registered under the Securities Act of 1933, as amended. The securities
may not be sold, transferred or assigned in the absence of an effective registration statement for the securities under said Act,
or an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, that registration
is not required under said Act or unless sold pursuant to Rule 144 or Regulation S under said Act.”

The
legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security
upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for
sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation
S without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) the
Company is provided with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions,
to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion
shall be accepted by the Company so that the sale or transfer is effected. The Investor agrees to sell all Securities, including
those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery
requirements, in any.

h.                 
Authorization; Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed
and delivered on behalf of the Investor, and this Agreement constitutes a valid and binding agreement of the Investor enforceable
in accordance with its terms.

i.                   
Residency. The Investor is a resident of the jurisdiction set forth in Section 8(f) herein.

3.                 
REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to the Investor that:

a.                 
Organization and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation
duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full
power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where
now owned, leased, used, operated and conducted. Schedule 3(a) sets forth a list of all of the Subsidiaries of the Company
and the jurisdiction in which each is incorporated. The Company and each of its Subsidiaries is duly qualified as a foreign corporation
to do business and is in good standing in every jurisdiction in which its ownership or use of property or the nature of the business
conducted by it makes such qualification necessary except where the failure to be so qualified or in good standing would not have
a Material Adverse Effect. “Material Adverse Effect” means any material and adverse effect on the business,
operations, assets, financial condition or prospects of the Company and the Subsidiaries, if any, taken as a whole, or on the
transactions contemplated hereby or by the agreements or instruments to be entered into in connection herewith. “Subsidiaries”
means any corporation or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly,
any equity or other ownership interest.

b.                 
Authorization; Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform
this Agreement and the Securities to consummate the transactions contemplated hereby and thereby and to issue the Securities,
in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement and the Note and Warrants by
the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the
issuance of the Note and Warrants, and the issuance and reservation for issuance of the Conversion Shares issuable upon conversion
or exercise thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization
of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered
by the Company by its authorized representative, and such authorized representative is the true and official representative with
authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and
(iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, Warrants and Registration Rights
Agreement, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable against
the Company in accordance with its terms.

    	3

    	 

    

c.                  
Capitalization.  As of the date hereof, the authorized capital stock of the Company consists of (i)_____________
shares of Common Stock, of which _____________  shares are issued and outstanding, shares are reserved for issuance pursuant to
the Company’s stock option plans, [ ] shares are reserved for issuance pursuant to securities (other than the Note) exercisable
for, or convertible into or exchangeable for shares of Common Stock and, shares are reserved for issuance upon conversion of the
Note and (subject to adjustment pursuant to the Company’s covenant set forth in Section 4(h) below); and (ii) 1,500 
shares of preferred stock of which 100 shares are issued and outstanding. All of such outstanding shares of capital stock are,
or upon issuance will be, duly authorized, validly issued, fully paid and nonassessable. No shares of capital stock of the Company
are subject to preemptive rights or any other similar rights of the shareholders of the Company or any liens or encumbrances imposed
through the actions or failure to act of the Company. Except as disclosed in Schedule 3(c), as of the effective date of
this Agreement, (i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal,
agreements, understandings, claims or other commitments or rights of any character whatsoever relating to, or securities or rights
convertible into or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by
which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company
or any of its Subsidiaries, (ii) there are no agreements or arrangements under which the Company or any of its Subsidiaries is
obligated to register the sale of any of its or their securities under the 1933 Act and (iii) there are no anti-dilution or price
adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security holders)
that will be triggered by the issuance of the Notes. The Company has furnished to the Investor true and correct copies of the
Company’s Certificate of Incorporation as in effect on the date hereof (“Certificate of Incorporation”),
the Company’s By-laws, as in effect on the date hereof (the “By-laws”), and the terms of all securities
convertible into or exercisable for Common Stock of the Company and the material rights of the holders thereof in respect thereto.
The Company shall provide the Investor with a written update of this representation signed by the Company’s Chief Executive
or Chief Financial Officer on behalf of the Company as of the Closing Date.

d.                 
Issuance of Shares. The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the
Note and exercise of the Warrants and payment of the exercise price, in accordance with their respective terms, will be validly
issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof
and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will not impose personal
liability upon the holder thereof.

e.                  
Acknowledgment of Dilution. The Company understands and acknowledges the potentially dilutive effect to the Common
Stock upon the issuance of the Conversion Shares upon conversion of the Note or exercise of the Warrants respectively. The Company
further acknowledges that its obligation to issue Conversion Shares upon conversion of the Note or exercise of the Warrants in
accordance with this Agreement, the Note and Warrants is absolute and unconditional regardless of the dilutive effect that such
issuance may have on the ownership interests of other shareholders of the Company.

f.                  
No Conflicts. The execution, delivery and performance of this Agreement, the Registration Rights Agreement, Warrants
and the Note by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including,
without limitation, the issuance and reservation for issuance of the Conversion Shares ) will not (i) conflict with or result
in a violation of any provision of the Certificate of Incorporation or By-laws or (ii) violate or conflict with, or result in
a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent,
patent license or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations
of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected (except for such
conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the
aggregate, have a Material Adverse Effect). Neither the Company nor any of its Subsidiaries is in violation of its Certificate
of Incorporation, By-laws or other organizational documents and neither the Company nor any of its Subsidiaries is in default
(and no event has occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries in default)
under, and neither the Company nor any of its Subsidiaries has taken any action or failed to take any action that would give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which
the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries
is bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect.
The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as a Investor
owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity. Except as specifically
contemplated by this Agreement and as required under the 1933 Act and any applicable state securities laws, the Company is not
required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency,
regulatory agency, self regulatory organization or stock market or any third party in order for it to execute, deliver or perform
any of its obligations under this Agreement, the Note or the Warrant in accordance with the terms hereof or thereof or to issue
and sell the Note and Warrants in accordance with the terms hereof and to issue the Conversion Shares upon conversion of the Note,
or exercise of the Warrants. Except as disclosed in Schedule 3(f), all consents, authorizations, orders, filings and registrations
which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date
hereof. The Company is not in violation of the quotation requirements of the Over-the-Counter Bulletin Board (the “OTCBB”)
and does not reasonably anticipate that the Common Stock will be delisted by the OTCBB in the foreseeable future. The Company
and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

    	4

    	 

    

g.                 
SEC Documents; Financial Statements. The Company is subject to the reporting requirements of the Securities Exchange
Act of 1934, as amended (the “1934 Act”) and the Company has timely filed all reports, schedules, forms, statements
and other documents required to be filed by it with the SEC pursuant to the 1934 Act (all of the foregoing filed prior to the
date hereof and all exhibits included therein and financial statements and schedules thereto and documents (other than exhibits
to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC Documents”).
The Company has delivered to the Investor true and complete copies of the SEC Documents, except for such exhibits and incorporated
documents. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934
Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents,
at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
they were made, not misleading. None of the statements made in any such SEC Documents is, or has been, required to be amended
or updated under applicable law (except for such statements as have been amended or updated in subsequent filings prior the date
hereof). As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form
in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect
thereto. Such financial statements have been prepared in accordance with United States generally accepted accounting principles,
consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the
notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed
or summary statements) and fairly present in all material respects the consolidated financial position of the Company and its
consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as set forth in the financial
statements of the Company included in the SEC Documents, the Company has no liabilities, contingent or otherwise, other than (i)
liabilities incurred in the ordinary course of business subsequent to June 30, 2012 and (ii) obligations under contracts and commitments
incurred in the ordinary course of business and not required under generally accepted accounting principles to be reflected in
such financial statements, which, individually or in the aggregate, are not material to the financial condition or operating results
of the Company.

h.                 
Absence of Certain Changes. Since December 31, 2012, there has been no material adverse change and no material adverse
development in the assets, liabilities, business, properties, operations, financial condition, and results of operations or prospects
of the Company or any of its Subsidiaries.

i.                   
Absence of Litigation. There is no action, suit, claim, proceeding, inquiry or investigation before or by any court,
public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its
Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their
capacity as such, that could have a Material Adverse Effect. Schedule 3(i) contains a complete list and summary description
of any pending or threatened proceeding against or affecting the Company or any of its Subsidiaries, without regard to whether
it would have a Material Adverse Effect. The Company and its Subsidiaries are unaware of any facts or circumstances which might
give rise to any of the foregoing.

j.                   
Patents, Copyrights, etc. The Company and each of its Subsidiaries owns or possesses the requisite licenses or rights
to use all patents, patent applications, patent rights, inventions, know-how, trade secrets, trademarks, trademark applications,
service marks, service names, trade names and copyrights (“Intellectual Property”) necessary to enable it to
conduct its business as now operated and as presently contemplated to be operated in the future; there is no claim or action by
any person pertaining to, or proceeding pending, or to the Company’s knowledge threatened, which challenges the right of
the Company or of a Subsidiary with respect to any Intellectual Property necessary to enable it to conduct its business as now
operated and as presently contemplated to be operated in the future; to the best of the Company’s knowledge, the Company’s
or its Subsidiaries’ current and intended products, services and processes do not infringe on any Intellectual Property
or other rights held by any person; and the Company is unaware of any facts or circumstances which might give rise to any of the
foregoing. The Company and each of its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality
and value of their Intellectual Property.

k.                 
No Materially Adverse Contracts, Etc. Neither the Company nor any of its Subsidiaries is subject to any charter, corporate
or other legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers
has or is expected in the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party
to any contract or agreement which in the judgment of the Company’s officers has or is expected to have a Material Adverse
Effect.

l.                   
Tax Status. The Company and each of its Subsidiaries has made or filed all federal, state and foreign income and all
other tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent
that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all
unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount,
shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set
aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which
such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing
authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has not executed
a waiver with respect to the statute of limitations relating to the assessment or collection of any foreign, federal, state or
local tax. None of the Company’s tax returns is presently being audited by any taxing authority.

    	5

    	 

    

m.               
Certain Transactions. Except for arm’s length transactions pursuant to which the Company or any of its Subsidiaries
makes payments in the ordinary course of business upon terms no less favorable than the Company or any of its Subsidiaries could
obtain from third parties and other than the grant of stock options disclosed on Schedule 3(c), none of the officers, directors,
or employees of the Company is presently a party to any transaction with the Company or any of its Subsidiaries (other than for
services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from
any officer, director or such employee or, to the knowledge of the Company, any corporation, partnership, trust or other entity
in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

n.                 
Disclosure. All information relating to or concerning the Company or any of its Subsidiaries set forth in this Agreement
and provided to the Investor pursuant to Section 2(d) hereof and otherwise in connection with the transactions contemplated hereby
is true and correct in all material respects and the Company has not omitted to state any material fact necessary in order to
make the statements made herein or therein, in light of the circumstances under which they were made, not misleading. No event
or circumstance has occurred or exists with respect to the Company or any of its Subsidiaries or its or their business, properties,
prospects, operations or financial conditions, which, under applicable law, rule or regulation, requires public disclosure or
announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the Company’s
reports filed under the 1934 Act are being incorporated into an effective registration statement filed by the Company under the
1933 Act).

o.                 
Acknowledgment Regarding Investor’s Purchase of Securities. The Company acknowledges and agrees that the Investor
is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated
hereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or
in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any statement made by the
Investor or any of their respective representatives or agents in connection with this Agreement and the transactions contemplated
hereby is not advice or a recommendation and is merely incidental to the Investor’s purchase of the Securities. The Company
further represents to the Investor that the Company’s decision to enter into this Agreement has been based solely on the
independent evaluation of the Company and its representatives.

p.                 
No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf,
has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances
that would require registration under the 1933 Act of the issuance of the Securities to the Investor. The issuance of the Securities
to the Investor will not be integrated with any other issuance of the Company’s securities (past, current or future) for
purposes of any shareholder approval provisions applicable to the Company or its securities.

q.                 
No Brokers. The Company has taken no action which would give rise to any claim by any person for brokerage commissions,
transaction fees or similar payments relating to this Agreement or the transactions contemplated hereby.

r.                  
Permits; Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations,
licenses, permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and
operate its properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”),
and there is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of
the Company Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of
the Company Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. Since June 30, 2012, neither the Company nor any of its Subsidiaries
has received any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices
relating to possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse
Effect.

s.                  
Environmental Matters.

(i)                
There are, to the Company’s knowledge, with respect to the Company or any of its Subsidiaries or any predecessor of
the Company, no past or present violations of Environmental Laws (as defined below), releases of any material into the environment,
actions, activities, circumstances, conditions, events, incidents, or contractual obligations which may give rise to any common
law environmental liability or any liability under the Comprehensive Environmental Response, Compensation and Liability Act of
1980 or similar federal, state, local or foreign laws and neither the Company nor any of its Subsidiaries has received any notice
with respect to any of the foregoing, nor is any action pending or, to the Company’s knowledge, threatened in connection
with any of the foregoing. The term “Environmental Laws” means all federal, state, local or foreign laws relating
to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater,
land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened
releases of chemicals, pollutants contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous
Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand
letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated
or approved thereunder.

    	6

    	 

    

(ii)              
Other than those that are or were stored, used or disposed of in compliance with applicable law, no Hazardous Materials are
contained on or about any real property currently owned, leased or used by the Company or any of its Subsidiaries, and no Hazardous
Materials were released on or about any real property previously owned, leased or used by the Company or any of its Subsidiaries
during the period the property was owned, leased or used by the Company or any of its Subsidiaries, except in the normal course
of the Company’s or any of its Subsidiaries’ business.

(iii)            
There are no underground storage tanks on or under any real property owned, leased or used by the Company or any of its Subsidiaries
that are not in compliance with applicable law.

t.                   
Title to Property. The Company and its Subsidiaries have good and marketable title in fee simple to all real property
and good and marketable title to all personal property owned by them which is material to the business of the Company and its
Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in Schedule 3(t)
or such as would not have a Material Adverse Effect. Any real property and facilities held under lease by the Company and
its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as would not have a Material
Adverse Effect.

u.                 
Insurance. The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses
in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect. Upon written
request the Company will provide to Investor true and correct copies of all policies relating to directors’ and officers’
liability coverage, errors and omissions coverage, and commercial general liability coverage.

v.                 
Internal Accounting Controls. The Company and each of its Subsidiaries maintain a system of internal accounting controls
sufficient, in the judgment of the Company’s board of directors, to provide reasonable assurance that (i) transactions are
executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset
accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization
and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.

w.               
Foreign Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor any director, officer, agent, employee
or other person acting on behalf of the Company or any Subsidiary has, in the course of his actions for, or on behalf of, the
Company, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate
funds; violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or made any
bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or
employee.

x.                 
Solvency. The Company (after giving effect to the transactions contemplated by this Agreement) is solvent (i.e.,
its assets have a fair market value in excess of the amount required to pay its probable liabilities on its existing debts as
they become absolute and matured) and currently the Company has no information that would lead it to reasonably conclude that
the Company would not, after giving effect to the transaction contemplated by this Agreement, have the ability to, nor does it
intend to take any action that would impair its ability to, pay its debts from time to time incurred in connection therewith as
such debts mature. The Company did not receive a qualified opinion from its auditors with respect to its most recent fiscal year
end and, after giving effect to the transactions contemplated by this Agreement, does not anticipate or know of any basis upon
which its auditors might issue a qualified opinion in respect of its current fiscal year.

y.                 
No Investment Company. The Company is not, and upon the issuance and sale of the Securities as contemplated by this
Agreement will not be an “investment company” required to be registered under the Investment Company Act of 1940 (an
“Investment Company”). The Company is not controlled by an Investment Company.

    	7

    	 

    

z.                  
Breach of Representations and Warranties by the Company. If the Company breaches any of the representations or warranties
set forth in this Section 3, and in addition to any other remedies available to the Investor pursuant to this Agreement, it will
be considered an event of Default under Section 3.4 of the Note.

4.                 
COVENANTS.

a.                 
Best Efforts. The parties shall use their best efforts to satisfy timely each of the conditions described in Section
6 and 7 of this Agreement.

b.                 
Form D; Blue Sky Laws. The Company agrees to file a Form D with respect to the Securities as required under Regulation
D and to provide a copy thereof to the Investor promptly after such filing. The Company shall, on or before the Closing Date,
take such action as the Company shall reasonably determine is necessary to qualify the Securities for sale to the Investor at
the applicable closing pursuant to this Agreement under applicable securities or “blue sky” laws of the states of
the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken
to the Investor on or prior to the Closing Date.

c.                  
Use of Proceeds. The Company shall use the net proceeds from the sale of the Note for general working capital purposes.

d.                 
Right of First Refusal. Subject to the exemptions described below, the Company will not conduct any equity financing
(including debt with an equity component) (“Future Offerings”) during the period beginning on the Closing Date and
ending twelve (12) months following the Closing Date unless it shall have first delivered to the Investor, at least seventy-two
(72) hours prior to the closing of such Future Offering, a written notice describing the proposed Future Offering, including the
terms and conditions thereof and proposed definitive documentation to be entered into in connection therewith, and providing the
Investor an option during the seventy-two (72) hour period following delivery of such notice to purchase the securities being
offering in the Future Offering on the same terms as contemplated by such Future Offering (the limitations referred to in this
sentence and the preceding sentence are collectively referred to as the “Right of First Refusal”). In the event the
terms and conditions of a proposed Future Offering are amended in any respect after delivery of the notice to the Investor concerning
the proposed Future Offering, the Company shall deliver a new notice to the Investor describing the amended terms and conditions
of the proposed Future Offering and the Investor thereafter shall have an option during the seventy-two (72) hour period following
delivery of such new notice to purchase the securities being offered on the same terms as contemplated by such proposed Future
Offering, as amended. The foregoing sentence shall apply to successive amendments to the terms and conditions of any proposed
Future Offering. The Right of First Refusal shall not apply to any transaction involving (i) issuances of securities in a firm
commitment underwritten public offering (excluding a continuous offering pursuant to Rule 415 under the 1933 Act), or (ii) issuances
of securities as consideration for a merger, consolidation or purchase of assets, or in connection with any strategic partnership
or joint venture (the primary purpose of which is not to raise equity capital), or in connection with the disposition or acquisition
of a business, product or license by the Company. The Right of First Refusal also shall not apply to the issuance of securities
upon exercise or conversion of the Company’s options, warrants or other convertible securities outstanding as of the date
hereof or to the grant of additional options or warrants, or the issuance of additional securities, under any Company stock option
or restricted stock plan approved by the shareholders of the Company.

e.                  
Expenses. At the Closing, the Company shall reimburse the Investor for expenses incurred by them in connection with
the negotiation, preparation, execution, delivery and performance of this Agreement and the other agreements to be executed in
connection herewith (“Documents”), including, without limitation, attorneys’ and consultants’ fees and
expenses, transfer agent fees, fees for stock quotation services, fees relating to any amendments or modifications of the Documents
or any consents or waivers of provisions in the Documents, fees for the preparation of opinions of counsel, escrow fees, and costs
of restructuring the transactions contemplated by the Documents. When possible, the Company must pay these fees directly, otherwise
the Company must make immediate payment for reimbursement to the Investor for all fees and expenses immediately upon written notice
by the Investor or the submission of an invoice by the Investor. The Company’s obligation with respect to this transaction
is to reimburse Investor’s expense, which shall be $1,500.00.

f.                  
Financial Information. The Company agrees to send the following reports to the Investor until the Investor transfers,
assigns, or sells all of the Securities: (i) within ten (10) days after the filing with the SEC, a copy of its Annual Report
on Form 10-K its Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K; (ii) within one (1) day after release,
copies of all press releases issued by the Company or any of its Subsidiaries; and (iii) contemporaneously with the making
available or giving to the shareholders of the Company, copies of any notices or other information the Company makes available
or gives to such shareholders.

    	8

    	 

    

g.                 
Authorization and Reservation of Shares. The Company shall at all times have authorized, and reserved for the purpose
of issuance, a sufficient number of shares of Common Stock to provide for the full conversion or exercise of the outstanding Note
and Warrants and issuance of the Conversion Shares in connection therewith (based on the Conversion Price of the Note in effect
from time to time and number of shares of Common Stock issuable upon due exercise of the Warrants) and as otherwise required by
the Note and Warrants. The Company shall not reduce the number of shares of Common Stock reserved for issuance upon conversion
of Note or exercisable under the Warrants without the consent of the Investor. The Company shall at all times maintain the number
of shares of Common Stock so reserved for issuance at an amount (“Reserved Amount”) equal to no less than the
number of shares issuable upon full exercise of the Warrants and two (2) times the number that is then actually issuable upon
full conversion of the Note and Additional Notes (based on the Conversion Price of the Note). If at any time the number of shares
of Common Stock authorized and reserved for issuance (“Authorized and Reserved Shares”) is below the Reserved
Amount, the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares,
including, without limitation, calling a special meeting of shareholders to authorize additional shares to meet the Company’s
obligations herein, in the case of an insufficient number of authorized shares, obtain shareholder approval of an increase in
such authorized number of shares, and voting the management shares of the Company in favor of an increase in the authorized shares
of the Company to ensure that the number of authorized shares is sufficient to meet the Reserved Amount.

h.                 
Listing. The Company shall promptly secure the listing or quotation, as the case may be, of the Conversion Shares upon
each national securities exchange or automated quotation system, if any, upon which shares of Common Stock are then listed or
quoted, as the case may be, (subject to official notice of issuance) and, so long as the Investor owns any of the Securities,
shall maintain, so long as any other shares of Common Stock shall be so listed or quoted, as the case may be, such listing or
quotation, as the case may be, of all Conversion Shares from time to time issuable upon conversion of the Notes. The Company will
obtain and, so long as the Investor owns any of the Securities, maintain the listing or quotation, as the case may be, and trading
of its Common Stock on the OTCBB or any equivalent replacement exchange, the Nasdaq National Market (“Nasdaq”),
the Nasdaq SmallCap Market (“Nasdaq SmallCap”), the New York Stock Exchange (“NYSE”), or
the American Stock Exchange (“AMEX”) and will comply in all respects with the Company’s reporting, filing
and other obligations under the bylaws or rules of the Financial Industry Regulatory Authority (“FINRA”) and
such exchanges, as applicable. The Company shall promptly provide to the Investor copies of any notices it receives from the OTCBB
and any other exchanges or quotation systems on which the Common Stock is then listed or quoted, as the case may be, regarding
the continued eligibility of the Common Stock for listing or quotation, as the case may be, on such exchanges and quotation systems.

i.                   
Corporate Existence. So long as a Investor beneficially owns the Note or the Warrants, the Company shall maintain its
corporate existence and shall not sell all or substantially all of the Company’s assets, except in the event of a merger
or consolidation or sale of all or substantially all of the Company’s assets, where the surviving or successor entity in
such transaction (i) assumes the Company’s obligations hereunder and under the agreements and instruments entered into in
connection herewith and (ii) is a publicly traded corporation whose Common Stock is listed for trading on the OTCBB, Nasdaq, Nasdaq
SmallCap, NYSE or AMEX.

j.                   
No Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances
that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of
the Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval
provision applicable to the Company or its securities.

k.                 
Failure to Comply with the 1934 Act. So long as the Investor beneficially owns any of the Notes, the Company shall
comply with the reporting requirements of the 1934 Act; and the Company shall continue to be subject to the reporting requirements
of the 1934 Act.

l.                   
Breach of Covenants. If the Company breaches any of the covenants set forth in this Section 4, and in addition to any
other remedies available to the Investor pursuant to this Agreement, it will be considered an Event of Default pursuant to Section
3.4 of the Note.

    	9

    	 

    

5.                 
TRANSFER AGENT INSTRUCTIONS. The Company shall issue irrevocable instructions to its transfer agent to issue certificates,
registered in the name of the Investor or its nominee, for the Conversion Shares in such amounts as specified from time to time
by the Investor to the Company upon conversion of the Note or exercise of the Warrants, in accordance with the terms thereof (the
“Irrevocable Transfer Agent Instructions”). In the event that the Company proposes to replace its transfer
agent, the Company shall provide, prior to the effective date of such replacement, a fully execute Irrevocable Transfer Agent
Instruction in a form as initially delivered pursuant to this Agreement signed by the successor transfer agent to the Investor.
Prior to registration of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may be sold pursuant
to Rule 144 without any restriction as to the number of Securities as of a particular date that can then be immediately sold,
all such certificates shall bear the restrictive legend specified in Section 2(g) of this Agreement. The Company warrants that
(i) no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, and stop transfer instructions
to give effect to Section 2(f) hereof (in the case of the Conversion Shares, prior to registration of the Conversion Shares under
the 1933 Act or the date on which the Conversion Shares may be sold pursuant to Rule 144 without any restriction as to the number
of Securities as of a particular date that can then be immediately sold), will be given by the Company to its transfer agent and
that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided
in this Agreement and the Note; (ii) it will not direct its transfer agent not to transfer or delay, impair, and/or hinder its
transfer agent in transferring (or issuing)(electronically or in certificated form) any certificate for Conversion Shares to be
issued to the Investor upon conversion of or otherwise pursuant to the Securities as and when required by the Securities or this
Agreement; and (iii) it will not fail to remove (or direct its transfer agent not to remove or impair, delay, and/or hinder its
transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof). Nothing
in this Section shall affect in any way the Investor’s obligations and agreement set forth in Section 2(g) hereof to comply
with all applicable prospectus delivery requirements, if any, upon re-sale of the Securities. If a Investor provides the Company
with (i) an opinion of counsel in form, substance and scope customary for opinions in comparable transactions, to the effect that
a public sale or transfer of such Securities may be made without registration under the 1933 Act and such sale or transfer is
effected or (ii) the Investor provides reasonable assurances that the Securities can be sold pursuant to Rule 144, the Company
shall permit the transfer, and, in the case of the Conversion Shares , promptly instruct its transfer agent to issue one or more
certificates, free from restrictive legend, in such name and in such denominations as specified by the Investor. The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to the Investor, by vitiating the intent and purpose
of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations
under this Section 5 may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions
of this Section, that the Investor shall be entitled, in addition to all other available remedies, to an injunction restraining
any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or other security
being required.

6.                 
CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL. The obligation of the Company hereunder to issue and sell the
Securities to a Investor at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following
conditions thereto, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at
any time in its sole discretion:

a.                 
The Investor shall have executed this Agreement and delivered the same to the Company.

b.                 
The Investor shall have delivered the Purchase Price in accordance with Section 1(b) above.

c.                  
The representations and warranties of the Investor shall be true and correct in all material respects as of the date when
made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific
date), and the Investor shall have performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by this Agreement to be performed, satisfied or complied with by the Investor at or prior to the Closing Date.

d.                 
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization
having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated
by this Agreement.

7.                 
CONDITIONS TO THE INVESTOR’S OBLIGATION TO PURCHASE. The obligation of the Investor hereunder to purchase the
Note at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided
that these conditions are for the Investor’s sole benefit and may be waived by the Investor at any time in its sole discretion:

a.                 
The Company shall have executed this Agreement and delivered the same to the Investor.

b.                 
The Company shall have delivered to the Investor a duly executed Note, Warrant and Registration Rights Agreement in accordance
with Section 1(b) above.

    	10

    	 

    

c.                  
The Irrevocable Transfer Agent Instructions, in form and substance satisfactory to he Investor, shall have been delivered
to and acknowledged in writing by the Company’s Transfer Agent.

d.                 
The representations and warranties of the Company shall be true and correct in all material respects as of the date when made
and as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific
date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date.
The Investor shall have received a certificate or certificates, executed by the chief executive officer of the Company, dated
as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by the Investor including,
but not limited to certificates with respect to the Company’s Certificate of Incorporation, By-laws and Board of Directors’
resolutions relating to the transactions contemplated hereby.

e.                  
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization
having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated
by this Agreement.

f.                  
No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company; including,
without limitation, a change in the 1934 Act reporting status of the Company or the failure of the Company to be timely in it’s
1934 Act reporting obligations.

g.                 
The Conversion Shares shall have been authorized for quotation on the OTCBB and trading in the Common Stock on the OTCBB shall
not have been suspended by the SEC or the OTCBB.

h.                 
The Investor shall have received an officer’s certificate described in Section 3(c) above, dated as of the Closing Date.

8.                 
GOVERNING LAW; MISCELLANEOUS.

a.                 
Governing Law. THIS AGREEMENT SHALL BE ENFORCED, GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE PRINCIPLES OF
CONFLICT OF LAWS. THE PARTIES HERETO HEREBY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES FEDERAL COURTS LOCATED IN
NEW YORK, NEW YORK WITH RESPECT TO ANY DISPUTE ARISING UNDER THIS AGREEMENT, THE AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. BOTH PARTIES IRREVOCABLY WAIVE THE DEFENSE OF AN INCONVENIENT FORUM TO THE
MAINTENANCE OF SUCH SUIT OR PROCEEDING. BOTH PARTIES FURTHER AGREE THAT SERVICE OF PROCESS UPON A PARTY MAILED BY FIRST CLASS
MAIL SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON THE PARTY IN ANY SUCH SUIT OR PROCEEDING. NOTHING HEREIN
SHALL AFFECT EITHER PARTY’S RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW. BOTH PARTIES AGREE THAT A FINAL
NON-APPEALABLE JUDGMENT IN ANY SUCH SUIT OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT
ON SUCH JUDGMENT OR IN ANY OTHER LAWFUL MANNER. THE PARTY WHICH DOES NOT PREVAIL IN ANY DISPUTE ARISING UNDER THIS AGREEMENT SHALL
BE RESPONSIBLE FOR ALL FEES AND EXPENSES, INCLUDING ATTORNEYS’ FEES, INCURRED BY THE PREVAILING PARTY IN CONNECTION WITH
SUCH DISPUTE.

b.                 
Counterparts; Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall
be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts
have been signed by each party and delivered to the other party. This Agreement, once executed by a party, may be delivered to
the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering
this Agreement.

c.                  
Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect
the interpretation of, this Agreement.

    	11

    	 

    

d.                 
Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any
law shall not affect the validity or enforceability of any other provision hereof.

e.                  
Entire Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding
of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein,
neither the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters.
No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the party to be charged
with enforcement.

f.                  
Notices. Any notices required or permitted to be given under the terms of this Agreement shall be sent by certified
or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery
service) or by facsimile and shall be effective five (5) days after being placed in the mail, if mailed by regular United States
mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile,
in each case addressed to a party. The addresses for such communications shall be:

If
to the Company:

 

Nyxio
Technologies Corp.

2156
NE Broadway

Portland,
Oregon 97232

Attention: Giorgio Johnson

Telephone: (855) 436-6996

Facsimile:_____________

With
a copy to:

_____________,
Esq.

________________

________________

Telephone:
________________

Facsimile:
________________

 

 

If
to a Investor:

Continental
Equities, LLC

331
West 57th Street, Suite 206

New
York, NY 10019

With
copy to:

  

Sommer
& Schneider

1205
Franklin Avenue, Suite 110

Garden
City, NY 11530

Attn:
Joel Schneider

 

 

Each
party shall provide notice to the other party of any change in address.

    	12

    	 

    

g.                 
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and assigns. Neither the Company nor the Investor shall assign this Agreement or any rights or obligations hereunder without the
prior written consent of the other. Notwithstanding the foregoing, subject to Section 2(f), the Investor may assign its rights
hereunder to any person that purchases Securities in a private transaction from a Investor or to any of its “affiliates,”
as that term is defined under the 1934 Act, without the consent of the Company.

h.                 
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

i.                   
Survival. The representations and warranties of the Company and the agreements and covenants set forth in this Agreement
shall survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Investor.
The Company agrees to indemnify and hold harmless the Investor and all it’s officers, directors, employees and agents for
loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations,
warranties and covenants set forth in this Agreement, including advancement of expenses as they are incurred.

j.                   
Publicity. The Company and the Investor shall have the right to review a reasonable period of time before issuance
of any press releases, SEC, OTCBB or FINRA filings, or any other public statements with respect to the transactions contemplated
hereby; provided, however, that the Company shall be entitled, without the prior approval of the Investor, to make
any press release or SEC, OTCBB (or other applicable trading market) or FINRA filings with respect to such transactions as is
required by applicable law and regulations (although the Investor shall be consulted by the Company in connection with any such
press release prior to its release and shall be provided with a copy thereof and be given an opportunity to comment thereon).

k.                 
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

l.                   
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party.

m.               
Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to
the Investor by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges
that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach
or threatened breach by the Company of the provisions of this Agreement, that the Investor shall be entitled, in addition to all
other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions
restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without
the necessity of showing economic loss and without any bond or other security being required.

IN
WITNESS WHEREOF, the undersigned Investor and the Company have caused this Agreement to be duly executed as of the date first
above written.

NYXIO
TECHNOLOGIES CORP.

 

By:
/s/ Giorgio Johnson

Name:Giorgio
Johnson

Title:Chief
Executive Officer

 

CONTINENTAL
EQUITIES LLC

 

By:
/s/ Continental Equities LLC

 

    	13NYXIO
TECHNOLOGIES INC.

NON-EXCLUSIVE
DISTRIBUTORSHIP AGREEMENT

 

 

This
Non-Exclusive Distributorship Agreement
(“Agreement”) is entered into
between Nyxio Technologies
Inc., whose principal place of
business is 2156 NE Broadway St., Portland,
OR, 97232 (hereinafter
referred to as “Nyxio”),
and the following distributor
(hereinafter referred to as “Distributor”):

 

Harco
Industries, Inc.
333

South
Van Brunt St. 

Englewood,
NJ 07631

 

1. 
Appointment of Distributor.
Upon the terms and
conditions contained in this Agreement
and its attached Exhibit A
which are
incorporated herein by
reference, Nyxio
hereby appoints Distributor
as an non-exclusive distributor of the
Products (as defined
in Section 2 below),
and Distributor hereby accepts
such appointment. Nyxio
agrees to sell the Products
to Distributor and Distributor agrees
to purchase Products from Nyxio.
All purchases of
Products from Nyxio
shall be made solely
under the terms and
conditions of sale
set forth herein, or
as otherwise agreed.

 

2. 
Products. The
products manufactured, distributed or supplied by
Nyxio that are
subject to this Agreement (the “Products”)
are those referenced on Exhibit
A attached hereto.
Nyxio may at
any time and from time to time,
in its sole discretion and without
notice to Distributor, before
acceptance of an order from
Distributor, add, discontinue or
limit production or delivery
of any Product, change the
price of any Product, or modify
the specifications, design
or construction of any
Product, without liability and add
new or additional
models or products to its existing
line. Nyxio
will endeavor to provide reasonable
notice of such changes and
a revised copy of Exhibit A,
provided, however,
that Exhibit A shall automatically
and without further consent of
Distributor be deemed modified by
any changes Nyxio
may make
as contemplated above.

 

3. 
Distributor Duties.
 In addition to its other
obligations under this Agreement, Distributor
shall do the following:

 

(a)   
use its best endeavors to maximize
sales of the Products;

 

		(b)	promote
                                                                                                                                                        the
                                                                                                                                                        Nyxio
                                                                                                                                                        brand
                                                                                                                                                        name;

 

(c) 
) use such media and
advertising materials
and methods, including
but not limited to, catalogs, trade
and advertising and tradeshows,
as have been approved in writing
by Nyxio prior
to their use;

    	 

    	 

    

		(d)	employ
                                                                                                                                                         suitably
                                                                                                                                                         qualified
                                                                                                                                                         and
                                                                                                                                                         trained
                                                                                                                                                         staff;

 

(e) 
) maintain an adequate
sales network and such
other staff
as may
be required to promote
and sell Products and ensure
that customers are given
proper instructions and information
concerning the purchase and use
of the Products and provide
a proper after
sales service for Products;

 

(f) 
make no alteration, modification
or addition to the Products and
make no
representations nor give
any warranty or
guarantee or pledge
Nyxio’s credit in relation
to the Products other than
as agreed in writing by
Nyxio;

 

(g) 
at its own expense ensure that all
regulations and requirements relating
to the promotion, distribution and
resale of the Products are
complied with;

 

(h) 
provide sales reports to
Nyxio in the form
and frequency required
by Nyxio,
including details of sales
by model and
resale prices of the Distributor and
such other information
relating to the Distributor and
the sale of the
Products as Nyxio
may reasonably request
to keep itself informed concerning
demand for the Products;

 

(i)  
provide reports to Nyxio in
the form required
by Nyxio
of the forecasted sales
for the following
fiscal year;

 

(j)  
follow strictly Nyxio’s instructions
regarding safety and environmental
data with respect to storage,
repair, handling
or use of the products.

 

 4. Nyxio’s Obligations, and Services Available Through Nyxio.

 

(a) 
Nyxio shall provide upon Distributor’s
request, at no cost to Distributor,
English printed matter in reasonable quantities,
which include the Owner’s
Manual, brochures and
photographs.

 

(b) 
Nyxio will consider
requests for its assistance on
a case-by-case submission for
trade exhibitions and seminars,
with the hours, nature, timing
and costs for
such services to be negotiated
in advance.

 

(c) 
Nyxio will
consider requests
to provide technical, sales support
and training
to Distributor on a
case-by-case submission, with the hours, nature, timing
and cost for such
services to be negotiated in advance.

 

5.  Purchase Orders. Upon
the terms and subject to
the conditions contained herein,
Distributor shall be
entitled during the
Term of this Agreement to issue to Nyxio firm purchase orders (“Purchase
Orders”) requesting the sale
and delivery of Products for its
own account. All Purchase
Orders submitted to Nyxio by Distributor shall
be subject to acceptance by
Nyxio and shall not be binding upon Nyxio
until so accepted. Distributor agrees with Nyxio that any terms and
conditions in Distributor’s form of Purchase
Order that are not consistent
with this Agreement shall
be of no force or effect,
whether Nyxio accepts
the Purchase Order
in writing, by performance or otherwise, unless
the parties agree specifically
in writing to vary the terms
herein.  Nyxio reserves the right to reject any order for Products
for any reason,
including its evaluation in its sole discretion of Distributor’s creditworthiness.

 

 6. Price and Payment

 

(a) 
Price.  All prices
shall be calculated FOB
Distributor Dock, NJ, USA, unless
otherwise agreed between
the Distributor and Nyxio.
Nyxio shall sell Products to Distributor
hereunder at the
prices set forth
on Exhibit A to this Agreement.  Nyxio
shall have the right
to alter or amend
its Product prices
and any
discounts from time to time upon
notice to Distributor, and
such new prices shall be deemed
an amendment to Exhibit

A.
All Product prices
are exclusive of all Taxes
(as defined below).

 

    	2

    	 

    

(b) 
Payment. The purchase
price for Products sold under
this Agreement shall be due
and payable to Nyxio
(Attn: Accounts Receivable) at
its address herein
in full within 45 days of invoice
and payable in US Dollars,
unless otherwise agreed in
writing between
the parties.

 

(c) 
Taxes. Distributor shall be
solely responsible for, and
shall pay any and
all applicable sales, use, value added,
excise or property
taxes, and any and
all imposts(this is a tax
levied on goods brought
into a country
from another
country), customs, duties, consular
fees or charges related
to importation or
exportation, including, without
limitation, any tariffs, penalty
duties, antidumping duties,
or countervailing duties
and any
interest or penalties
in connection with the
foregoing (collectively
“Taxes”). Distributor
shall indemnify and hold harmless
Nyxio from any
liability for such
Taxes and other charges imposed
in connection therewith, with the intent that the
invoiced price
for Products shall be
paid in full net of all such Taxes
or charges.

 

7. 
Delivery and Risk.
Title to and all risk
of loss for the Products shall
pass from Nyxio to the Distributor
on delivery of the Products at Distributors
Dock, NJ, USA, except
as the parties may
otherwise agree in writing signed
by both parties. Nyxio
shall use reasonable efforts
to meet delivery
dates set forth in a Purchase Order,
if such dates
are confirmed by
Nyxio, but the
parties acknowledge and
agree that quantities and any
such delivery dates set forth
in any Purchase
Order, confirmation or other
correspondence are
not guaranteed.

 

8. 
Limited Warranty.  Nyxio
provides a limited warranty
to the purchaser of
Products, and there
is a separate limited warranty
for each product
sold by Nyxio.
Distributor agrees to pass
through the Nyxio
Limited Warranty to its dealers and
to cause its dealers
to pass the Nyxio Limited
Warranty through to the
end-users of the Products,
where applicable. EXCEPT AS EXPRESSLY
PROVIDED IN THIS
SECTION 10, NYXIO MAKES NO
REPRESENTATIONS OR WARRANTIES OF
ANY KIND, NATURE
OR DESCRIPTION, EXPRESS
OR IMPLIED,
INCLUDING, WITHOUT
LIMITATION, ANY WARRANTY OF MERCHANTABILITY
OR FITNESS OF
ANY PRODUCT
FOR ANY PARTICULAR PURPOSE, AND
HEREBY DISCLAIMS THE SAME.

 

 9. Limitation of Liability.

 

(a)  IN NO EVENT
SHALL THE LIABILITY OF NYXIO TO DISTRIBUTOR IN CONNECTION
WITH THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR UNDER ANY
OTHER LEGAL THEORY
(INCLUDING STRICT LIABILITY),
EXCEED THE AMOUNTS PAID BY
DISTRIBUTOR TO NYXIO DURING THE IMMEDIATELY PRECEDING
SIX (6) MONTHS.

 

(b) 
IN NO EVENT SHALL
NYXIO BE
LIABLE TO DISTRIBUTOR OR ANY
OTHER PERSON, WHETHER IN CONTRACT,
TORT OR UNDER ANY
OTHER LEGAL
THEORY, FOR LOST
PROFITS OR REVENUES, LOSS
OF USE OR SIMILAR
ECONOMIC LOSS,
FOR ANY INDIRECT,
SPECIAL, INCIDENTAL,
CONSEQUENTIAL OR SIMILAR DAMAGES
ARISING OUT OF
OR IN CONNECTION
WITH THE SALE, DELIVERY,
NON-DELIVERY, SERVICING, USE,
CONDITION, OWNERSHIP,
POSSESSION, OPERATION, SELECTION,
TRANSPORTATION, LOADING,
UNLOADING, MAINTENANCE OR RETURN
OF A PRODUCT,
OR FOR ANY CLAIM
MADE AGAINST DISTRIBUTOR
BY ANY OTHER
PARTY, EVEN IF
NYXIO HAS BEEN
ADVISED OF THE
POSSIBILITY OF SUCH CLAIM.

 

(c) 
DISTRIBUTOR SHALL INSPECT
ALL PRODUCTS AS SOON AS
PRACTICABLE AFTER THE DATE OF RECEIPT.
ANYTHING HEREIN TO THE
CONTRARY NOTWITHSTANDING, TO
THE EXTENT
THAT ANY DEFECTS,
SHORTAGES OR NONCONFORMITIES IN
THE PRODUCTS ARE DISCOVERABLE
BY INSPECTION
UPON RECEIPT OF THE
PRODUCTS BY DISTRIBUTOR,
ALL OBLIGATIONS OF NYXIO
TO DISTRIBUTOR WITH
RESPECT TO SUCH DEFECTS, SHORTAGES
OR NONCONFORMITIES SHALL BE
DEEMED TO BE SATISFIED,
AND ALL PRODUCTS SHALL
BE DEEMED TO
BE FREE OF
SUCH DEFECTS, SHORTAGES OR NONCONFORMITIES,
UNLESS DISTRIBUTOR NOTIFIES
NYXIO OF SUCH DEFECTS,
SHORTAGES OR NONCONFORMITIES
IN WRITING WITHIN THIRTY
(30) DAYS AFTER THE DATE
OF RECEIPT.

 

(d) 
NO ACTION, REGARDLESS OF FORM,
ARISING OUT OF OR
IN CONNECTION WITH THE SALE
OF PRODUCTS UNDER THIS
AGREEMENT (OTHER THAN
AN ACTION BY
NYXIO FOR
ANY AMOUNT DUE
TO NYXIO FROM
DISTRIBUTOR UNDER SECTION
8 HEREOF OR OTHERWISE OR WITH
RESPECT TO DISTRIBUTOR’S OBLIGATIONS
UNDER SECTIONS 14 AND
15 HEREOF) MAY BE
BROUGHT MORE THAN ONE
(1) YEAR AFTER THE
CAUSE OF ACTION
HAS ARISEN.

 

    	3

    	 

    

10. 
. Relationship of
Parties.
Distributor is not the agent or legal representative
of Nyxio for
any purpose
whatsoever. Distributor is not granted any
right or authority to
assume or to create any
obligation or responsibility,
express or
implied, on behalf of or
in the name of Nyxio, or to bind
Nyxio in any
manner whatsoever.

 

11. 
. Indemnification.
Distributor hereby agrees to
indemnify Nyxio against all
proceedings, claims,
losses, costs (including professional
fees), damages and expenses
which may
be incurred or suffered
by or threatened against
Nyxio as a result of any breach
or alleged breach
by the Distributor
of any of
the provisions of this Agreement or
any activities of
the Distributor pursuant to this Agreement.

 

12. License; Intellectual Property.

 

(a) 
Products License.
Nyxio hereby
grants to Distributor a limited,
non- exclusive, non-assignable
or transferable, revocable, right
and license to market and sell
the Products subject to the provisions
of this Agreement. As a condition
to the license granted
herein, Distributor agrees not to challenge
in any manner
whatsoever, the validity of
any of
Nyxio’s patents or other Intellectual
Property (as defined
below), and any
such challenge shall constitute
a material breach of
the terms of this Agreement.

 

(b) 
Trademarks and
Copyrights. Distributor
shall distribute
the Products only
as branded with the
Nyxio trademarks
and copyrights as designated
by Nyxio
from time to time. Accordingly,
Nyxio grants
Distributor during the
Term a non-exclusive,
non-assignable, revocable, non-transferable
right to use Nyxio’s trademarks
and copyrights in distributing
the Products and any copyrighted promotional
materials, manuals
or literature, subject to Distributor’s
strict compliance with the terms
of Nyxio’s
policies on the use of
its trademarks and copyrights,
as in effect from time
to time during
the Term.

 

(c) 
Limitations. Except
for the rights expressly
granted to Distributor in this
Agreement, nothing in
this Agreement grants
Distributor, by implication,
estoppel or otherwise,
any right
or license under any copyright, trademark,
logo, tradename, trade secret,
patent right, moral right or
any other industrial or intellectual
property or other proprietary
right (“Intellectual
Property”) of
Nyxio or associated with
the Products. Without limiting
the generality
of the foregoing,
Distributor may not modify,
disassemble, reverse-engineer
or create derivative
products, enhancements
or improvements (“Improvements”)
based on any Nyxio
products including the
Products, nor may Distributor,
directly or indirectly, use
or allow others
to use the Products or any
other Nyxio products
or product information
to develop products that
compete with or are
substitutable for the Products
or any other
Nyxio products.

 

 13. . Confidentiality.

 

(a) 
Definitions. For purposes of this
Agreement the term “Confidential
Information” shall mean
information and compilations of information
relating to Nyxio’s
business and Products known and
made available only to
Nyxio and such
of its authorized agents,
employees, customers, representatives
and other persons as may
be necessary
for the same to be
used, including, without limitation:
information relating to
Nyxio’s customers;
compilations and lists of Nyxio’s
customers; price and
cost information
with respect to the
Products or other products of Nyxio;
technical information, formulas,
data, designs, specifications
and know-how (whether
or not patented
or patentable) relating
to the design, development or manufacture
of the Products
or any other
Nyxio product. Such information
and compilations of information
shall be contractually subject to protection
pursuant to the provisions of this Agreement
without regard to whether such
information would otherwise
be regarded or
legally considered “confidential”
and without regard to whether
such information constitutes
a trade secret and is
also protectable at
law or in equity
as a trade secret.

 

(b)  Covenant
Against Disclosure or Use of Confidential
Information. Distributor agrees
that it will not, and will not permit
any of its employees, agents, or affiliates (or any of their respective
employees or agents) to,
during this agreement and for five years thereafter
use or disclose to any third person
any Confidential Information obtained by Distributor
(or any of
its employees or affiliates); provided, however, that Distributor
may make disclosures required by a valid order
or subpoena issued by a
court or administrative agency of
competent jurisdiction.  In such event,
Distributor shall promptly notify Nyxio of such
order or subpoena to provide Nyxio an
opportunity to protect
its interests.

 

    	4

    	 

    

(c) 
Exceptions. Notwithstanding
the provisions of Section
15(b) above, the following
shall not be considered Confidential
Information:

 

(i)  
any
information
which was known to Distributor prior
to the disclosure to it of any
portion of the Confidential
Information, as evidenced
by prior
existing records of
Distributor;

 

(ii)  
any information
which was generally
known in the trade prior
to the disclosure of any
portion of the Confidential Information
to Distributor, as evidenced
by documents
of general circulation published prior
to such disclosure;

 

(iii)  
any information which becomes
generally known in the trade,
as evidenced
by documents
of general circulation, through
no fault of Distributor; or

 

(iv)  
any
information
which is disclosed to Distributor without restriction
by a
third party who has
a legal right to make
such disclosure and who has not
received such information, either
directly or indirectly,
from Nyxio.

 

(d) 
Survival; Interpretation.
The provisions
of strict confidence, secrecy and
non-use set forth in this Section
15 shall survive the expiration
or termination (for
any reason) of
this Agreement.

 

 14. Termination.

 

(a) 
Termination Rights.
 Either party
may terminate this Agreement
at any
time, for any
reason, by
giving not less
than thirty (30) days
prior written notice
to the other party.
 In
addition, Nyxio
may terminate this Agreement
immediately (or immediately
following the expiration of
the time periods set forth
below), and without any liability
to Distributor, upon the occurrence of
any one or more
of the following events:

 

(i)  
The failure by Distributor
to pay the purchase price
for any Products
in accordance with this Agreement,
which failure remains uncured
for a period of fifteen (15) days
following the due date thereof;

 

(ii)  
The breach by Distributor
of any
term or provision of this Agreement,
which breach is not cured within
thirty (30) days
following Distributor’s
receipt of
notice from Nyxio of
such breach;

 

(iii)   Any attempt by Distributor to assign
or otherwise transfer to any other person or entity, all or
any part of its rights under
this Agreement or to delegate all or
any part of its
obligations under this Agreement without
the prior written consent
of Nyxio;

 

(iv)  
The insolvency of
Distributor or any action
causing Distributor to avail itself
of laws for the protection of
debtors including, without limitation,
the appointment of
a receiver or the like, a complete
or partial moratorium on
the payment of debt,
a petition in bankruptcy or the like
filed by
or against Distributor, or
an assignment of all or any
substantial portion of the assets
of Distributor for the benefit of its creditors;
or

 

(v) 
In
the event there is a
change in the control
or management of
Distributor which is unacceptable to
Nyxio, or Distributor ceases to function
as a going
concern, or ceases to conduct
its operation in the normal course
of business as
a Distributor.

 

(b) 
Distributor Termination Rights.
Distributor shall have the right
to terminate this Agreement
in the event of a material
breach by Nyxio of
this Agreement, which
breach is not cured within thirty (30)
days following
Nyxio’s receipt of written
notice from Distributor of such
breach.

 

(c) 
Effect of Termination.
Distributor agrees that on expiration
or termination of
this Agreement (with or without
cause) Nyxio shall not be liable
for any termination
compensation whatsoever whether
based on goodwill established or
investments made by
Distributor or otherwise.
Upon expiration or termination
of this Agreement
for any
reason (i) all orders
received from Distributor but not
shipped by
Nyxio prior to the
date of termination may be
shipped by Nyxio
or canceled, at Nyxio’s
option, and Distributor agrees
to accept shipment of
and make payment for
any such orders
shipped by Nyxio;
 and (ii)
Nyxio shall have the right (but
not the obligation), in Nyxio’s
sole discretion, upon ten (10)
days prior written notice
to Distributor, to repurchase all
or any Products in the possession
or control of Distributor at
the time of such notice at the
purchase prices paid therefore by
Distributor.

 

    	5

    	 

    

(d) 
Return of Confidential
Information. Upon
termination of this
Agreement, each
party agrees
upon request to promptly return
to the other all
documents, records, papers, materials
and other tangible property
which is the
other party’s
Confidential Information.

 

(e) 
Survival. Payment of
all outstanding amounts
shall be settled in full upon notice
of termination. Termination of
this Agreement shall be
without prejudice to the accrued
rights and remedies of the
parties under this Agreement, and the
obligations. The undertakings
of the parties contained
in Sections 7, 9, 10, 12, 13(c), 14, this Section
16, and Sections 18 through
23 shall remain in force in accordance
with their terms notwithstanding
such termination.

 

15.  Force Majeure. Neither party shall
be liable to the other nor be deemed
to be in default of this Agreement as
a result of any delay or failure in
performing its obligations under
this Agreement as a
result of any delay or failure in
performing its obligations under this Agreement
to the extent that any such delay or failure
arises from causes
beyond the control of that
Party including, but not limited to, acts of God, acts
or regulations of any governmental or supranational
authority, war or national emergency,
accident, fire, riot, strikes, lock-outs
and industrial disputes.

 

16. 
Waiver. No failure
on the part of Nyxio to exercise,
and no delay by
Nyxio in exercising
any right,
power or remedy hereunder shall
operate as
a waiver thereof, nor
shall any single or
partial exercise of any
right, power or remedy by
Nyxio preclude
any other
or further exercise thereof
or the exercise
of any other right,
power or remedy. No express
waiver or assent
by Nyxio
to any breach of
or default in any
term or condition of this Agreement
shall constitute a waiver
of or an assent to any succeeding
breach of or
default in the same
or any other
term or condition hereof.

 

17. 
. Notice.
Any notice
or notification that the
parties shall give in connection
with this Agreement, shall be
in writing and must be addressed
to the corresponding party at
its address given
below or to the facsimile
number below (or to such
other address or facsimile
number as
either party may
from time to time duly notify
the other):

 

Nyxio
Technologies Inc.

2156
NE Broadway St.

Portland, OR, 97232

Attn: President

Fax
Number: 503-954-2780

 

18. 
Governing Law. All matters
relating to the interpretation
and effect of
the terms of
this Agreement or any
amendments thereto shall be
governed by the
laws of the State
of Oregon, United States
of America. The
parties agree to waive
personal jurisdiction and venue in
any dispute relating
to the enforcement of this Agreement
and agree that any
dispute between Nyxio and Distributor
shall be exclusively
resolved in the Courts of Multnomah
County, Oregon. The
parties acknowledge and agree
that the Products sold
hereunder and this Agreement
are not subject to any
provision of the United Nations
Convention on the International
Sale of Goods.

 

19. 
. Headings.
The headings describing
the contents of particular Sections
are inserted only
for convenience
and shall not be construed as
a part of this Agreement
or as a limitation on or enlargement
of the scope of any
of the terms or
provisions of this Agreement.

 

20. 
Severability. All rights
and restrictions contained herein may
be exercised and shall
be applicable and
binding only
to the extent that they do not
violate any applicable
laws and are
intended to be limited to the extent necessary so that
they will not render this
Agreement illegal, invalid or
unenforceable.  If
any term of
this Agreement shall be held
to be illegal, invalid or unenforceable
by a
court of competent jurisdiction,
it is the intention of the parties that
the remaining terms
hereof shall constitute their agreement
with respect to the subject matter
hereof, and all
such remaining terms shall
remain in full force
and effect.

    	6

    	 

    

 

21.
.. Entire Agreement. This Agreement,
which includes its exhibits, supersedes all priord iscussions and
agreements between the parties with respect to
the subject matter hereof,
and this Agreement contains the sole
and entire agreement between the
parties with respect to
the matters covered hereby.  By
way of illustration and not by way of limitation,
all Purchase Orders submitted by Distributor hereunder shall
be deemed to incorporate without exception
all of the terms of this Agreement
notwithstanding any order form
containing additional or contrary
terms and conditions, unless Nyxio
shall expressly advise
Distributor to the contrary in writing apart from
the provisions of such order form, and
no acknowledgment by Nyxio
of or reference by Nyxio
to or performance by Nyxio under
any such order form shall
be deemed to be an
acceptance by Nyxio of
any such additional or
contrary terms or conditions. This Agreement
may not be modified or amended except by an
instrument in writing signed by the
parties or their duly authorized
representatives, except that
Exhibit A may be amended
from time to time as specifically provided
for in this Agreement without Distributor’s
written authorization.

 

IN
WITNESS
WHEREOF, the parties have
caused this Agreement to be
executed under
seal as of the day
and year
first above written.

 

Nyxio:

 

NYXIO
TECHNOLOGIES, INC.

 

By:
/s/  Giorgio Johnson

Name:

Title:

 

Distributor:

 

HARCO
INDUSTRIES, INC.

 

By:
 /s/ Harco Industries, Inc.

 

 

*******************
Exhibit A Products and Price

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]